clinical trial · NCT07591519
Clinical Trials of IBI3035 in Healthy Subjects
Innovent Biologics (Suzhou) Co. Ltd.·phase1·recruiting·n = 144
Healthy PersonIBI3035Insulin icodec Injection
brief summary
This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects
started
May 8, 2026
primary completion
Jul 30, 2027
completion
Aug 31, 2027
last updated
Jul 16, 2026
official title
Evaluation of the Pharmacokinetics and Pharmacodynamics of IBI3035 and Awiqli? (Ecoporin Insulin Injection) in a Randomized, Open-label, Single-dose, Two-formulation, Crossover Design in Healthy Male Subjects in China: A Phase I Clinical Trial.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol